Literature DB >> 26390846

Clinical guidelines: Addressing comorbidities in systemic inflammatory disorders.

Tristan Boyd1, Arthur Kavanaugh2.   

Abstract

Mesh：

Year:  2015        PMID： 26390846     DOI： 10.1038/nrrheum.2015.129

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

1.  Rheumatoid arthritis: Guidelines for RA therapy-avoiding hamartia.

Authors:  Arthur Kavanaugh
Journal:  Nat Rev Rheumatol       Date:  2010-09       Impact factor: 20.543

Review 2.  Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative.

Authors:  Camille Roubille; Vincent Richer; Tara Starnino; Collette McCourt; Alexandra McFarlane; Patrick Fleming; Stephanie Siu; John Kraft; Charles Lynde; Janet Pope; Wayne Gulliver; Stephanie Keeling; Jan Dutz; Louis Bessette; Robert Bissonnette; Boulos Haraoui
Journal:  J Rheumatol       Date:  2015-07-15       Impact factor: 4.666

Review 3.  Recognizing and managing comorbidities in psoriatic arthritis.

Authors:  Alexis Ogdie; Sergio Schwartzman; M Elaine Husni
Journal:  Curr Opin Rheumatol       Date:  2015-03       Impact factor: 5.006

Review 4.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

5.  The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs.

Authors:  Helga Radner; Kazuki Yoshida; Michelle Frits; Christine Iannaccone; Nancy A Shadick; Michael Weinblatt; Josef S Smolen; Daniel H Solomon
Journal:  Rheumatology (Oxford)       Date:  2015-07-10       Impact factor: 7.580

6.  Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011.

Authors:  April W Armstrong; Clayton Schupp; Bruce Bebo
Journal:  Dermatology       Date:  2012-10-26       Impact factor: 5.366

7.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-10-25       Impact factor: 19.103

8.  Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).

Authors:  Maxime Dougados; Martin Soubrier; Anna Antunez; Peter Balint; Alejandro Balsa; Maya H Buch; Gustavo Casado; Jacqueline Detert; Bassel El-Zorkany; Paul Emery; Najia Hajjaj-Hassouni; Masayoshi Harigai; Shue-Fen Luo; Reka Kurucz; Gabriel Maciel; Emilio Martin Mola; Carlo Maurizio Montecucco; Iain McInnes; Helga Radner; Josef S Smolen; Yeong-Wook Song; Harald Erwin Vonkeman; Kevin Winthrop; Jonathan Kay
Journal:  Ann Rheum Dis       Date:  2013-10-04       Impact factor: 19.103

9.  Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers.

Authors:  Matteo Nicola Dario Di Minno; Rosario Peluso; Salvatore Iervolino; Anna Russolillo; Roberta Lupoli; Raffaele Scarpa
Journal:  Ann Rheum Dis       Date:  2013-06-14       Impact factor: 19.103
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.